Patents by Inventor Minako AIHARA

Minako AIHARA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Technology for efficient activation of NKT cells
    Patent number: 11744860
    Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 5, 2023
    Assignees: RIKEN, AMBICION CO., LTD.
    Inventors: Masaru Taniguchi, Tomokuni Shigeura, Minako Aihara, Keigo Hanada
  • TECHNOLOGY FOR EFFICIENT ACTIVATION OF NKT CELLS
    Publication number: 20190134094
    Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 9, 2019
    Applicants: RIKEN, AMBICION CO., LTD.
    Inventors: Masaru TANIGUCHI, Tomokuni SHIGEURA, Minako AIHARA, Keigo HANADA